Aston University spin out Aston Particle Technologies (APT) has closed a £1 million funding round according to lead investor DSW Ventures. The funding will be used for scale up of APT's isothermal dry particle coating (iDPC) technology, which DSW said is useful for high dose DPI formulations among other uses. DSW explained that the expanded cGMP capacity is necessary … [Read more...] about Aston Particle Technologies gets £1 million in funding
News
Spirovant opens new lab and headquarters
Sumitovant subsidiary Spirovant Sciences, which is developing inhaled gene therapies for the treatment of cystic fibrosis, has opened a new research laboratory and corporate headquarters in Philadelphia, PA, USA, the company said. Spirovant's SP-101 inhaled adeno-associated virus (AAV) gene therapy for CF has been granted orphan disease and rare pediatric disease … [Read more...] about Spirovant opens new lab and headquarters
Positive Phase 1 results for Pneumagen’s Neumifil antiviral nasal spray
Pneumagen has announced that a Phase 1 dose escalation study of its Neumifil carbohydrate binding module nasal spray demonstrated that the nasal spray was well tolerated and had no dose limiting toxicity. Pneumagen announced the initiation of the Phase 1 trial in November 2021. The company previously announced data from pre-clinical studies showing that Neumifil has … [Read more...] about Positive Phase 1 results for Pneumagen’s Neumifil antiviral nasal spray
Alembic gets FDA approval for its arforoterol tartrate inhalation solution
According to Indian generics developer Alembic Pharmaceuticals, the company's ANDA for a generic version of Sunovion's Brovana arformoterol tartrate inhalation solution for the treatment of COPD has received final FDA approval. Alembic co-developed the arformoterol inhalation solution with Indian CRO Orbicular Pharmaceutical Technologies. The ANDA approval is … [Read more...] about Alembic gets FDA approval for its arforoterol tartrate inhalation solution
Pieris warns of potential delays in clinical trial of PRS-060/AZD1402 DPI
In a business update, Pieris Pharmaceuticals warned that an ongoing clinical trial of its dry powder PRS-060/AZD1402 IL-4 receptor alpha inhibitor may take longer than expected, saying "Given the geopolitical situation, along with broader challenges amidst an ongoing pandemic, there is a heightened risk that more time will be required to deliver the topline study … [Read more...] about Pieris warns of potential delays in clinical trial of PRS-060/AZD1402 DPI
Nebu-Flow closes £1.7 million funding round
Scottish nebulizer developer Nebu-Flow has raised £1.7 million "to continue the commercialization and delivery of next generation respiratory pharmaceuticals," the company has announced on social media. The funding round was led by Foresight Williams Technology. Nebu-Flow was spun out from the University of Glasgow in 2019 to develop a device based on surface acoustic … [Read more...] about Nebu-Flow closes £1.7 million funding round
Zeteo Biomedical launches ZEOx1 OrionMRQ nasal delivery device
Zeteo Biomedical has announced the launch of its ZEOx1 OrionMRQ metered dose nasal device for delivery of drugs and vaccines. Zeteo's ZEOx1 devices are designed for intranasal delivery of liquid formulations, and its ZEOx2 devices are designed for intranasal delivery of powders, reconstituted powders, or multiple liquid formulations. In November 2020, Zeteo said that … [Read more...] about Zeteo Biomedical launches ZEOx1 OrionMRQ nasal delivery device
Galenica to provide GMP manufacturing for clinical trial supplies of Iconovo’s ICOone inhaler
DPI developer Iconovo has announced that Galenica AB will offer cGMP manufacturing of Iconovo's ICOone single dose disposable DPI for clinical trials, so that customers wanting to develop an inhaled drug delivered by the ICOone device have an accelerated option for producing clinical trial supplies. According to the announcement, close cooperation between the … [Read more...] about Galenica to provide GMP manufacturing for clinical trial supplies of Iconovo’s ICOone inhaler
Proveris names Ramesh Chand as Associate Director of Proveris Laboratories
Proveris Scientific has named Ramesh Chand as Associate Director of Proveris Laboratories, the company's contract testing business, which launched in May 2020. Chand was most recently Principal Scientist in Respiratory Drug Product Development at Moderna and previously held positions in OINDP research at GSK, Lovelace Biomedical, and Amneal … [Read more...] about Proveris names Ramesh Chand as Associate Director of Proveris Laboratories
Kindeva Drug Delivery acquires iPharma Labs
Kindeva Drug Delivery, formerly 3M Drug Delivery Systems, has announced that it will acquire inhaled drug CRO iPharma Labs, and iPharma's team of well-known OINDP specialists will join Kindeva. Founded in 2016, iPharma extended its offerings in 2020 to include GLP/GMP development services for inhaled drugs. The iPharma team will remain in its existing facilities in … [Read more...] about Kindeva Drug Delivery acquires iPharma Labs